Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors. Siegall… Read More
Clay Siegall is proud of his legacy as co-founder and longtime CEO of Seagen, the largest biotech company in the Seattle area. “I built a great company,” Siegall said in… Read More
Seagen founder Clay Siegall is jumping back into the biotech world as CEO and president of Morphimmune. Founded in 2020, the Purdue University spinout will relocate its headquarters to the… Read More
Clay Siegall, the former CEO and chairman of Seattle-area biotech giant Seagen, will not face charges stemming from an arrest at his home in April. The Seattle Times first reported… Read More
Clay Siegall has resigned as CEO and chairman of Seagen in the midst of domestic violence allegations, more than 24 years after the biotech veteran helped start the publicly traded… Read More
Seagen is expanding its manufacturing capacity in the Seattle area. The fast-growing global biotech company will build a 270,000 square-foot facility to make antibody-based drugs north of its U.S. headquarters… Read More
Shares of cancer drug maker Seattle Genetics soared more than 17 percent Monday morning following positive results for a new drug that fights aggressive breast cancers. Tucatinib is a daily… Read More
Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading. Quarterly revenues came in at $175 million, above Wall Street expectations… Read More